Position in MLYS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$12,135,469
New position
Shares Held
449,795
first reported quarter
Ownership
0.509%
of shares outstanding
% of Portfolio
2.09%
of 13F equity value
Holder Rank
#50
of 224 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Prosight Management, LP holds $415,390,745 across 22 Biotechnology names. MLYS ranks #12 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LKFT |
Lakefront Biotherapeutics NV
|
2,043,344 | $61,259,453 | |
| 2 | JANX |
Janux Therapeutics, Inc.
|
3,804,481 | $58,436,828 | |
| 3 | NKTR |
Nektar Therapeutics
|
810,000 | $56,546,100 | |
| 4 | STTK |
Shattuck Labs, Inc.
|
5,957,877 | $41,347,666 | |
| 5 | INSM |
INSMED Inc
|
375,609 | $40,047,431 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
98,080 | $29,525,022 | |
| 7 | SNDX |
Syndax Pharmaceuticals Inc
|
1,200,000 | $26,232,000 | |
| 8 | KURA |
Kura Oncology, Inc.
|
2,021,964 | $22,180,945 |
All Filings in MLYS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,135,469 | 449,795 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||